请输入您要查询的百科知识：

　

词条 GW501516
释义

  1. History

     Performance-enhancing drug 

  2. Mode of action

  3. See also

  4. References

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458657924
| IUPAC_name = {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid
| image = GW501,516.svg
| width = 270
| tradename =
| legal_AU = Scheduled as illegal from June 2018
| legal_US = unscheduled
| legal_UK = unscheduled
| routes_of_administration = oral
| pregnancy_category = N/A
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 317318-70-0
| ATC_prefix = none
| PubChem = 9803963
| ChemSpiderID = 7979723
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7I2HA1NU22
| IUPHAR_ligand = 2687
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 73726
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 38943
| C=21 | H=18 | F=3 | N=1 | O=3 | S=2
| molecular_weight = 453.498 g/mol
| smiles = O=C(COc1ccc(SCc2c(C)nc(c3ccc(C(F)(F)F)cc3)s2)cc1C)O
| StdInChI = 1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
| StdInChIKey = YDBLKRPLXZNVNB-UHFFFAOYSA-N
}}GW501516 (also known as GW-501,516, GW1516, GSK-516, Cardarine, and on the black market as Endurobol[1]) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.[2]

In 2007 research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a black market for the drug candidate and to its abuse by athletes as a doping agent. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.

History

GW501516 was initially discovered during a research collaboration between GSK and Ligand Pharmaceuticals that began in 1992.[2] The discovery of the compound was published in a 2001 issue of PNAS.[3] Oliver et al. reported that they used "combinatorial chemistry and structure-based drug design" to develop it.[4] One of the authors was the son of Leo Sternbach who discovered benzodiazepines in the 1960s.[5]

R & D Focus Drug News reported that GSK began phase I trials of the compound for the treatment of hyperlipidemia in 2000[6] followed by phase I/II in 2002.[7] In 2003, Ligand Pharmaceuticals earned a $1 million payment as a result of GSK continuing phase I development.[8]

By 2007, GW501516 had completed two phase II clinical studies and other studies relating to obesity, diabetes, dyslipidemia and cardiovascular disease,[9][10] but GSK abandoned further development of the drug in 2007 for reasons which were not disclosed at the time.[11] It later emerged that the drug was discontinued because animal testing showed that the drug caused cancer to develop rapidly in several organs, at dosages of 3 mg/kg/day in both mice and rats.[12][13][14]

Ronald M. Evans's laboratory purchased a sample of GW501516 and gave mice a much higher dose than had been used in GSK's experiments; they found that the compound dramatically increased the physical performance of the mice. The work was published in 2007 in Cell and was widely reported in the popular press including The New York Times and The Wall Street Journal.[15]

Performance-enhancing drug

Concerns were raised prior to the 2008 Beijing Olympics that GW501516 could be used by athletes as an ergogenic performance-enhancing drug that was not currently controlled by regulations or detected by standard tests. One of the main researchers from the study on enhanced endurance consequently developed a urine test to detect the drug, and made it available to the International Olympic Committee. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related PPARδ modulators,[16] and added such drugs to the prohibited list in 2009.[17]

GW501516 has been promoted on bodybuilding and athletics websites[18] and by 2011 had already been available for some time on the black market.[1][19] In 2011 it was reported to cost $1000 for 10 g.[15] In 2012, WADA recategorised GW501516 from a gene doping compound to a "hormone and metabolic modulator".[20]

In 2013, WADA took the rare step of warning potential users of the compound of the possible health risks, stating that "clinical approval has not, and will not be given for this substance"; the New Scientist attributed the warning to the risks of the drug causing cancer.[18][21]

A number of athletes have tested positive for GW501516. At the Vuelta Ciclista a Costa Rica in December 2012, four Costa Rican riders tested positive for GW501516. Three of them received two-year suspensions, while the fourth received 12 years as it was his second doping violation.[22][23][24] In April 2013, Russian cyclist Valery Kaykov was suspended by cycling's governing body UCI after having tested positive for GW501516. Kaykov's team RusVelo dismissed him immediately[25] and in May 2013, Venezuelan Miguel Ubeto was provisionally suspended by the Lampre team.[26] In February 2014, Russian race walker Elena Lashmanova tested positive for GW501516.[27][28]

Mode of action

GW501516 is a selective agonist (activator) of the PPARδ receptor.[29] It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.[4]

In rats, binding of GW501516 to PPARδ recruits the coactivator PGC-1α. The PPARδ/coactivator complex in turn upregulates the expression of proteins involved in energy expenditure.[35] Furthermore, in rats treated with GW501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL).[30]

See also

  • Acadesine
  • GFT505
  • GW0742
  • Irisin
  • Peroxisome proliferator-activated receptor
  • Sodelglitazar
  • SR9009

References

1. ^1 {{cite web|url=http://theconversation.com/anti-doping-agency-warns-cheats-on-the-health-risks-of-endurobol-12997|title=Anti-doping agency warns cheats on the health risks of Endurobol |publisher=The Conversation|date=2013-03-22}}
2. ^{{cite news|title=GW501516 GlaxoSmithKline, Ligand milestone payment.|date=28 June 2004|publisher=R & D Focus Drug News}}
3. ^{{cite journal | author = Wolf G | title = The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis | journal = Nutr. Rev. | volume = 61 | issue = 11 | pages = 387–90 |date=November 2003 | pmid = 14677574 | doi = 10.1301/nr.2003.nov.387-390 }}
4. ^1 {{cite journal | vauthors = Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM | title = A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 98 | issue = 9 | pages = 5306–11 |date=April 2001 | pmid = 11309497 | pmc = 33205 | doi = 10.1073/pnas.091021198 }}
5. ^{{cite news|url=https://www.wsj.com/articles/0,,SB107644751774825922,00|title=Father and Son: In Two Generations, Drug Research Sees a Big Shift|publisher=The Wall Street Journal|author=Julia Flynn|date=11 February 2004}}{{Dead link|date=July 2018 |bot=InternetArchiveBot |fix-attempted=yes }}
6. ^{{cite news|title=GW501516 Glaxo Wellcome phase change I, UK|date=20 November 2000|publisher=R & D Focus Drug News}}
7. ^{{cite news|title=GW501516 GlaxoSmithKline phase change II, UK|date=25 February 2002|publisher=R & D Focus Drug News}}
8. ^{{cite news|url=http://www.businesswire.com/news/home/20030604005732/en/Ligand-Earns-1-Million-Milestone-Payment-GlaxoSmithKline|title=Ligand Pharmaceuticals Incorporated Earns $1 Million Milestone Payment as GlaxoSmithKline Advances Development of 501516|date=5 June 2003|publisher=Reuters Significant Developments}}
9. ^{{cite journal | vauthors = Barish GD, Narkar VA, Evans RM | title = PPAR delta: a dagger in the heart of the metabolic syndrome | journal = J. Clin. Invest. | volume = 116 | issue = 3 | pages = 590–7 |date=March 2006 | pmid = 16511591 | pmc = 1386117 | doi = 10.1172/JCI27955 | url = }}
10. ^{{cite journal | author = Uwe Dressel | author2 = Tamara L. Allen | author3 = Jyotsna B. Pippal| author4 = Paul R. Rohde | author5 = Patrick Lau | author6 = George E. O. Musc | last-author-amp = yes| title = The Peroxisome Proliferator-Activated Receptor β/δ Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells | journal = Molecular Endocrinology | issue =12 | pages = 2477–93 | year = 2003 |doi=10.1210/me.2003-0151 | url = http://mend.endojournals.org/content/17/12/2477.short |pmid=14525954 | volume = 17 }}
11. ^{{cite journal | author = Billin AN | title = PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home | journal = Expert Opin Investig Drugs | volume = 17 | issue = 10 | pages = 1465–71 |date=October 2008 | pmid = 18808307 | doi = 10.1517/13543784.17.10.1465 }}
12. ^1 {{cite journal | vauthors = Sahebkar A, Chew GT, Watts GF | title = New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease | journal = Expert Opin Pharmacother | volume = 15 | issue = 4 | pages = 493–503 | year = 2014 | pmid = 24428677 | doi = 10.1517/14656566.2014.876992 | quote = Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes }}
13. ^{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 895 - Rat carcinogenicity study with GW501516, a PPAR delta agonist | vauthors = Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ | date = 2009 | publisher = Society of Toxicology | page = 105 }}
14. ^{{cite conference | conference = 48th Annual Meeting of the Society of Toxicology | location = Baltimore | url = http://www.toxicology.org/AI/Pub/Tox/2009Tox.pdf | archive-url = https://web.archive.org/web/20150504013406/http://www.toxicology.org/AI/PUB/Tox/2009Tox.pdf | archivedate = 2015-05-04 | title = PS 896 - Mouse carcinogenicity study with GW501516, a PPAR delta agonist. | vauthors = Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE | date = 2009 | publisher = Society of Toxicology | page = 105 }}
15. ^1 {{cite web|url=http://www.outsideonline.com/outdoor-adventure/natural-intelligence/Faster--Higher--Squeakier-.html?page=all|title=Faster. Higher. Squeakier.|publisher=Outside magazine|author=Michael Bezar|date=2011-11-01|accessdate=2013-04-02}}
16. ^{{cite web | url = https://www.independent.co.uk/life-style/health-and-wellbeing/health-news/warning-to-beijing-olympics-over-pills-that-mimic-exercise-882608.html | title = Warning to Beijing Olympics over pills that mimic exercise | vauthors = Laurance J, Rajan A | authorlink = | date = 2008-08-01 | work = Health News, Health & Wellbeing | publisher = The Independent | pages = | accessdate = 2008-08-01 }}
17. ^WADA 2009 Prohibited List {{webarchive |url=https://web.archive.org/web/20090203030039/http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf |date=February 3, 2009 }}
18. ^1 {{cite news|url=https://www.newscientist.com/article/mg21729103-400-anti-doping-agency-warns-athletes-of-black-market-drug/|title=Anti-doping agency warns athletes of black market drug |publisher=New Scientist|date=2013-03-26}}
19. ^{{cite journal | vauthors = Thevis M, Geyer H, Thomas A, Schänzer W | title = Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet | journal = Drug Test Anal | volume = 3 | issue = 5 | pages = 331–6 |date=May 2011 | pmid = 21538997 | doi = 10.1002/dta.283 }}
20. ^{{cite journal | vauthors = Sanchis-Gomar F, Lippi G | title = Telmisartan as metabolic modulator: a new perspective in sports doping? | journal = J Strength Cond Res | volume = 26 | issue = 3 | pages = 608–10 |date=March 2012 | pmid = 22130396 | doi = 10.1519/JSC.0b013e31824301b6 }}
21. ^{{cite web|url=https://www.wada-ama.org/en/media/news/2013-03/wada-issues-alert-on-gw501516|title=WADA issues alert on GW501516|publisher=World Anti-Doping Agency|date=2013-03-21|archiveurl=https://web.archive.org/web/20130602050612/http://playtrue.wada-ama.org/news/wada-issues-alert-on-gw501516/|archivedate=June 2, 2013}}
22. ^Shane Stokes: GW501516 positives confirmed, three of four riders are from same BCR Pizza Hut team, velonation.com, 15 April 2013
23. ^Shane Stokes: Four riders each handed two year bans for use of GW501516, velonation.com 30 July 2013
24. ^List of sanctions {{webarchive |url=https://web.archive.org/web/20140715214800/http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTU3Mjg&ObjTypeCode=FILE&type=FILE&id=Nzk5OTY&LangId=1 |date=July 15, 2014 }}, uci.ch
25. ^{{cite news|url=https://www.bbc.co.uk/sport/0/cycling/22111802|title=European champion Valery Kaykov sacked for failing drug test|publisher=BBC|date=2013-04-11|accessdate=2013-04-11}}
26. ^{{cite news|url=http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|archive-url=https://archive.is/20130628075943/http://www.uci.ch/Modules/ENews/ENewsDetails.asp?source=SiteSearch&id=OTI3Ng&MenuId=MTI2Mjg|dead-url=yes|archive-date=2013-06-28|title=Miguel Ubeto Aponte provisionally suspended|publisher=UCI|date=2013-05-13|accessdate=2013-05-15}}
27. ^Sanctioned athletes list – 26 June 2014
28. ^Associated Press: Doping probe launched into Russian walkers, espn.com, 11 July 2014
29. ^{{cite journal | author = Pelton P | title = GW501516 GlaxoSmithKline/Ligand | journal = Curr Opin Investig Drugs | volume = 7 | issue = 4 | pages = 360–70 |date=April 2006 | pmid = 16625823 | doi = | url = }}
30. ^1 {{cite journal | author = Sprecher DL | title = Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta | journal = Am. J. Cardiol. | volume = 100 | issue = 11 A | pages = n20–4 |date=December 2007 | pmid = 18047848 | doi = 10.1016/j.amjcard.2007.08.009 }}
{{PPAR modulators}}

9 : PPAR agonists|GlaxoSmithKline|GlaxoSmithKline brands|Carcinogens|Experimental drugs|Trifluoromethyl compounds|Thioethers|Thiazoles|Carboxylic acids
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/30 4:14:54